China’s fast-track clinical trials are in the spotlight after child deaths
Summary
The deaths of children in gene-therapy studies have intensified scrutiny of China’s fast-track clinical-trial system. A new government policy aims to preserve rapid innovation while strengthening safety oversight.
The decisive issue is whether faster approvals have outpaced monitoring and disclosure obligations. China must
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
The policy will determine whether China can remain a leading destination for advanced therapies without sacrificing patient protection.